Search - tctmd.com

Displaying 141 - 160 of 334

Sort: Relevancy | Date

Presentation TCT 2018

Pharmacotherapy Challenges and Possible Solutions in the PCI Patient on Chronic Oral Anticoagulation

Presenter: Davide Capodanno, Giulio Stefanini, Tullio Palmerini

September 23, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Presentation TCT 2018

DAPT and Anticoagulation Post TAVR: What is the Standard of Care?

Presenter: Martina Kelly Speight, Patricia Keegan

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

Presentation TCT 2018

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

Presenter: John A. Bittl, C. Michael Gibson, Dimitrios Alexopoulos

September 23, 2018

Presentation TCT 2018

The Case for Bivalirudin With Radial (and Femoral) Access

Presenter: John A. Bittl, C. Michael Gibson, Carey D. Kimmelstiel

September 23, 2018

Presentation TCT 2018

The Latest Antithrombotic Data: MATRIX at 1 Year

Presenter: John A. Bittl, C. Michael Gibson, Stephan Windecker

September 23, 2018

Presentation TCT 2018

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Presenter: John A. Bittl, C. Michael Gibson, Matthew J. Price

September 23, 2018

Presentation TCT 2018

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Presenter: John A. Bittl, C. Michael Gibson, Giuseppe Tarantini

September 23, 2018

Presentation TCT 2018

Featured Lecture: Does the Polypill Enhance Drug Adherence and Improve Cardiovascular Outcomes?

Presenter: John A. Bittl, C. Michael Gibson, Valentin Fuster

September 23, 2018

Presentation TCT 2018

Featured Lecture: The High-risk Patient: Risk Assessment and Current Recommendations for DAPT and OAC

Presenter: Bagrat Alekyan, Juan F. Granada, Roxana Mehran

September 22, 2018

Presentation TCT 2018

Considerations for LAA Closure Devices: FDA Perspective

Presenter: Andrew Farb

September 22, 2018

Presentation TCT 2018

Point to Consider in the Review of the LAAC Related Devices: Japanese Regulatory View: PMDA

Presenter: Akihide Konishi

September 22, 2018

Presentation TCT 2018

The Current Target Population for LAAC Closure Based on the Results of Clinical Trials in Europe

Presenter: Marek Grygier

September 22, 2018

Presentation TCT 2018

The Overview of Clinical Trials and Current Target Population for LAAC Closure

Presenter: Shephal Doshi

September 22, 2018

Presentation TCT 2018

Clinical Trials for Short DAPT: FDA Perspective

Presenter: Christopher J Popma

September 22, 2018

Presentation TCT 2018

The Current Situation of DAPT for Coronary DES in US

Presenter: Mitchell W. Krucoff

September 22, 2018

Advertisement

Pharmacotherapy Challenges and Possible Solutions in the PCI Patient on Chronic Oral Anticoagulation

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

DAPT and Anticoagulation Post TAVR: What is the Standard of Care?

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

The Case for Bivalirudin With Radial (and Femoral) Access

The Latest Antithrombotic Data: MATRIX at 1 Year

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Featured Lecture: Does the Polypill Enhance Drug Adherence and Improve Cardiovascular Outcomes?

Featured Lecture: The High-risk Patient: Risk Assessment and Current Recommendations for DAPT and OAC

Considerations for LAA Closure Devices: FDA Perspective

Point to Consider in the Review of the LAAC Related Devices: Japanese Regulatory View: PMDA

The Current Target Population for LAAC Closure Based on the Results of Clinical Trials in Europe

The Overview of Clinical Trials and Current Target Population for LAAC Closure

Clinical Trials for Short DAPT: FDA Perspective

The Current Situation of DAPT for Coronary DES in US

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content